Search

Your search keyword '"Lanktree MB"' showing total 4 results
Start Over Author "Lanktree MB" Publication Type Electronic Resources

Refine your results

4 results on '"Lanktree MB"'

1. ACLY and CKD: A Mendelian Randomization Analysis.

Author

Mohammadi-Shemirani, P, Chong, M, Perrot, N, Pigeyre, M, Steinberg, GR, Paré, G, Krepinsky, JC, Lanktree, MB, Mohammadi-Shemirani, P, Chong, M, Perrot, N, Pigeyre, M, Steinberg, GR, Paré, G, Krepinsky, JC, and Lanktree, MB

Abstract

INTRODUCTION: Adenosine triphosphate-citrate lyase (ACLY) inhibition is a therapeutic strategy under investigation for atherosclerotic cardiovascular disease, nonalcoholic steatohepatitis, and metabolic syndrome. Mouse models suggest that ACLY inhibition could reduce inflammation and kidney fibrosis. Genetic analysis of ACLY in chronic kidney disease (CKD) has not been performed. METHODS: We constructed a genetic instrument by selecting variants associated with ACLY expression in the expression quantitative trait loci genetics consortium (eQTLGen) from blood samples from 31,684 participants. In a 2-sample Mendelian randomization analysis, we evaluated the effect of genetically predicted ACLY expression on the risk of CKD, estimated glomerular filtration rate (eGFR), and albumin-to-creatinine ratio (ACR) using the CKD Genetics (CKDGen) consortium, UK Biobank, and the Finnish Genetics (FinnGen) consortium totaling 66,396 CKD cases and 958,517 controls. RESULTS: ACLY is constitutively expressed in all cell types including in whole blood. The genetic instrument included 13 variants and explained 1.5% of the variation in whole blood ACLY gene expression. A 34% reduction in ACLY expression score was associated with a 0.04 mmol/l reduced low-density lipoprotein (LDL) cholesterol (P = 3.4 × 10-4) and a 9% reduced risk of CKD (stages 3, 4, 5, dialysis, or eGFR < 60 ml/min per 1.73 m2) (odds ratio [OR] = 0.91, 95% CI: 0.85-0.98, P = 0.008), but no association was observed with either eGFR or ACR. CONCLUSION: Mendelian randomization analyses revealed that genetically reduced ACLY expression was associated with reduced risk of CKD but had no effect on either eGFR or ACR. Further evaluation of ACLY in kidney disease is warranted.

Published
2022

2. Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Koettgen, A, Cornec-Le Gall, E, Halbritter, J, Kiryluk, K, Mallett, AJ, Parekh, RS, Rasouly, HM, Sampson, MG, Tin, A, Antignac, C, Ars, E, Bergmann, C, Bleyer, AJ, Bockenhauer, D, Devuyst, O, Florez, JC, Fowler, KJ, Franceschini, N, Fukagawa, M, Gale, DP, Gbadegesin, RA, Goldstein, DB, Grams, ME, Greka, A, Gross, O, Guay-Woodford, LM, Harris, PC, Hoefele, J, Hung, AM, Knoers, NVAM, Kopp, JB, Kretzler, M, Lanktree, MB, Lipska-Zietkiewicz, BS, Nicholls, K, Nozu, K, Ojo, A, Parsa, A, Pattaro, C, Pei, Y, Pollak, MR, Rhee, EP, Sanna-Cherchi, S, Savige, J, Sayer, JA, Scolari, F, Sedor, JR, Sim, X, Somlo, S, Susztak, K, Tayo, BO, Torra, R, van Eerde, AM, Weinstock, A, Winkler, CA, Wuttke, M, Zhang, H, King, JM, Cheung, M, Jadoul, M, Winkelmayer, WC, Gharavi, AG, Koettgen, A, Cornec-Le Gall, E, Halbritter, J, Kiryluk, K, Mallett, AJ, Parekh, RS, Rasouly, HM, Sampson, MG, Tin, A, Antignac, C, Ars, E, Bergmann, C, Bleyer, AJ, Bockenhauer, D, Devuyst, O, Florez, JC, Fowler, KJ, Franceschini, N, Fukagawa, M, Gale, DP, Gbadegesin, RA, Goldstein, DB, Grams, ME, Greka, A, Gross, O, Guay-Woodford, LM, Harris, PC, Hoefele, J, Hung, AM, Knoers, NVAM, Kopp, JB, Kretzler, M, Lanktree, MB, Lipska-Zietkiewicz, BS, Nicholls, K, Nozu, K, Ojo, A, Parsa, A, Pattaro, C, Pei, Y, Pollak, MR, Rhee, EP, Sanna-Cherchi, S, Savige, J, Sayer, JA, Scolari, F, Sedor, JR, Sim, X, Somlo, S, Susztak, K, Tayo, BO, Torra, R, van Eerde, AM, Weinstock, A, Winkler, CA, Wuttke, M, Zhang, H, King, JM, Cheung, M, Jadoul, M, Winkelmayer, WC, and Gharavi, AG

Abstract

Numerous genes for monogenic kidney diseases with classical patterns of inheritance, as well as genes for complex kidney diseases that manifest in combination with environmental factors, have been discovered. Genetic findings are increasingly used to inform clinical management of nephropathies, and have led to improved diagnostics, disease surveillance, choice of therapy, and family counseling. All of these steps rely on accurate interpretation of genetic data, which can be outpaced by current rates of data collection. In March of 2021, Kidney Diseases: Improving Global Outcomes (KDIGO) held a Controversies Conference on "Genetics in Chronic Kidney Disease (CKD)" to review the current state of understanding of monogenic and complex (polygenic) kidney diseases, processes for applying genetic findings in clinical medicine, and use of genomics for defining and stratifying CKD. Given the important contribution of genetic variants to CKD, practitioners with CKD patients are advised to "think genetic," which specifically involves obtaining a family history, collecting detailed information on age of CKD onset, performing clinical examination for extrarenal symptoms, and considering genetic testing. To improve the use of genetics in nephrology, meeting participants advised developing an advanced training or subspecialty track for nephrologists, crafting guidelines for testing and treatment, and educating patients, students, and practitioners. Key areas of future research, including clinical interpretation of genome variation, electronic phenotyping, global representation, kidney-specific molecular data, polygenic scores, translational epidemiology, and open data resources, were also identified.

Published
2022

4. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data

Author

Holmes, MV, Dale, CE, Zuccolo, L, Silverwood, RJ, Guo, Y, Ye, Z, Prieto-Merino, D, Dehghan, Abbas, Trompet, S, Wong, A, Cavadino, A, Drogan, D, Padmanabhan, S, Li, Shan, Yesupriya, A, Leusink, M, Sundstrom, J, Hubacek, JA, Pikhart, H, Swerdlow, DI, Panayiotou, AG, Borinskaya, SA, Finan, C, Shah, S, Kuchenbaecker, KB, Shah, T, Engmann, J, Folkersen, L, Eriksson, P, Ricceri, F, Melander, O, Sacerdote, C, Gamble, DM, Rayaprolu, S, Ross, OA, McLachlan, S, Vikhireva, O, Sluijs, Iris, Scott, RA, Adamkova, V, Flicker, L, van Bockxmeer, FM, Power, C, Marques-Vidal, P, Meade, T, Marmot, MG, Ferro, JM, Paulos-Pinheiro, S, Humphries, SE, Talmud, PJ, Leach, IM, Verweij, N (Niek), Linneberg, A, Skaaby, T, Doevendans, PA, Cramer, MJ, van der Harst, P, Klungel, OH, Dowling, NF, Dominiczak, AF, Kumari, M, Nicolaides, AN, Weikert, C, Boeing, H, Ebrahim, S, Gaunt, TR, Price, JF, Lannfelt, L, Peasey, A, Kubinova, R, Pajak, A, Malyutina, S, Voevoda, MI, Tamosiunas, A, Zee, AH, Norman, PE, Hankey, GJ, Bergmann, MM, Hofman, Bert, Franco Duran, OH, Cooper, J, Palmen, J, Spiering, W, Jong, PA, Kuh, D, Hardy, R, Uitterlinden, André, Ikram, Arfan, Ford, I, Hyppoenen, E, Almeida, OP, Wareham, NJ, Khaw, KT, Hamsten, A, Husemoen, LLN, Tjonneland, A, Tolstrup, JS, Rimm, E, Beulens, JWJ, Verschuren, WMM, Onland-Moret, NC, Hofker, MH, Wannamethee, SG, Whincup, PH, Morris, R, Vicente, AM, Watkins, H, Farrall, M, Jukema, JW, Meschia, J, Cupples, LA, Sharp, SJ, Fornage, M, Kooperberg, C, Lacroix, AZ, Dai, JY, Lanktree, MB, Siscovick, DS, Jorgenson, E, Spring, B, Coresh, J, Li, YR, Buxbaum, SG, Schreiner, PJ, Ellison, RC, Tsai, MY, Patel, SR, Redline, S, Johnson, AD, Hoogeveen, RC, Rotter, JI, Boerwinkle, E, de Bakker, PIW, Kivimaki, M, Asselbergs, FW, Sattar, N, Lawlor, DA, Whittaker, J, Smith, GD, Mukamal, K, Psaty, BM, Wilson, JG, Lange, LA, Hamidovic, A, Hingorani, AD, Nordestgaard, BG, Bobak, M, Leon, DA, Langenberg, C, Palmer, TM, Reiner, AP, Keating, BJ, Dudbridge, F, Casas, JP, Holmes, MV, Dale, CE, Zuccolo, L, Silverwood, RJ, Guo, Y, Ye, Z, Prieto-Merino, D, Dehghan, Abbas, Trompet, S, Wong, A, Cavadino, A, Drogan, D, Padmanabhan, S, Li, Shan, Yesupriya, A, Leusink, M, Sundstrom, J, Hubacek, JA, Pikhart, H, Swerdlow, DI, Panayiotou, AG, Borinskaya, SA, Finan, C, Shah, S, Kuchenbaecker, KB, Shah, T, Engmann, J, Folkersen, L, Eriksson, P, Ricceri, F, Melander, O, Sacerdote, C, Gamble, DM, Rayaprolu, S, Ross, OA, McLachlan, S, Vikhireva, O, Sluijs, Iris, Scott, RA, Adamkova, V, Flicker, L, van Bockxmeer, FM, Power, C, Marques-Vidal, P, Meade, T, Marmot, MG, Ferro, JM, Paulos-Pinheiro, S, Humphries, SE, Talmud, PJ, Leach, IM, Verweij, N (Niek), Linneberg, A, Skaaby, T, Doevendans, PA, Cramer, MJ, van der Harst, P, Klungel, OH, Dowling, NF, Dominiczak, AF, Kumari, M, Nicolaides, AN, Weikert, C, Boeing, H, Ebrahim, S, Gaunt, TR, Price, JF, Lannfelt, L, Peasey, A, Kubinova, R, Pajak, A, Malyutina, S, Voevoda, MI, Tamosiunas, A, Zee, AH, Norman, PE, Hankey, GJ, Bergmann, MM, Hofman, Bert, Franco Duran, OH, Cooper, J, Palmen, J, Spiering, W, Jong, PA, Kuh, D, Hardy, R, Uitterlinden, André, Ikram, Arfan, Ford, I, Hyppoenen, E, Almeida, OP, Wareham, NJ, Khaw, KT, Hamsten, A, Husemoen, LLN, Tjonneland, A, Tolstrup, JS, Rimm, E, Beulens, JWJ, Verschuren, WMM, Onland-Moret, NC, Hofker, MH, Wannamethee, SG, Whincup, PH, Morris, R, Vicente, AM, Watkins, H, Farrall, M, Jukema, JW, Meschia, J, Cupples, LA, Sharp, SJ, Fornage, M, Kooperberg, C, Lacroix, AZ, Dai, JY, Lanktree, MB, Siscovick, DS, Jorgenson, E, Spring, B, Coresh, J, Li, YR, Buxbaum, SG, Schreiner, PJ, Ellison, RC, Tsai, MY, Patel, SR, Redline, S, Johnson, AD, Hoogeveen, RC, Rotter, JI, Boerwinkle, E, de Bakker, PIW, Kivimaki, M, Asselbergs, FW, Sattar, N, Lawlor, DA, Whittaker, J, Smith, GD, Mukamal, K, Psaty, BM, Wilson, JG, Lange, LA, Hamidovic, A, Hingorani, AD, Nordestgaard, BG, Bobak, M, Leon, DA, Langenberg, C, Palmer, TM, Reiner, AP, Keating, BJ, Dudbridge, F, and Casas, JP

Abstract

Objective To use the rs1229984 variant in the alcohol dehydrogenase 1B gene (ADH1B) as an instrument to investigate the causal role of alcohol in cardiovascular disease. Design Mendelian randomisation meta-analysis of 56 epidemiological studies. Participants 261 991 individuals of European descent, including 20 259 coronary heart disease cases and 10 164 stroke events. Data were available on ADH1B rs1229984 variant, alcohol phenotypes, and cardiovascular biomarkers. Main outcome measures Odds ratio for coronary heart disease and stroke associated with the ADH1B variant in all individuals and by categories of alcohol consumption. Results Carriers of the A-allele of ADH1B rs1229984 consumed 17.2% fewer units of alcohol per week (95% confidence interval 15.6% to 18.9%), had a lower prevalence of binge drinking (odds ratio 0.78 (95% CI 0.73 to 0.84)), and had higher abstention (odds ratio 1.27 (1.21 to 1.34)) than non-carriers. Rs1229984 A-allele carriers had lower systolic blood pressure (-0.88 (-1.19 to -0.56) mm Hg), interleukin-6 levels (-5.2% (-7.8 to -2.4%)), waist circumference (-0.3 (-0.6 to -0.1) cm), and body mass index (-0.17 (-0.24 to -0.10) kg/m(2)). Rs1229984 A-allele carriers had lower odds of coronary heart disease (odds ratio 0.90 (0.84 to 0.96)). The protective association of the ADH1B rs1229984 A-allele variant remained the same across all categories of alcohol consumption (P= 0.83 for heterogeneity). Although no association of rs1229984 was identified with the combined subtypes of stroke, carriers of the A-allele had lower odds of ischaemic stroke (odds ratio 0.83 (0.72 to 0.95)). Conclusions Individuals with a genetic variant associated with non-drinking and lower alcohol consumption had a more favourable cardiovascular profile and a reduced risk of coronary heart disease than those without the genetic variant. This suggests that reduction of alcohol consumption, even for light to moderate drinkers, is beneficial for cardiovascular health.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results